Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in: Archives of Dermatological Research 3/2014

Open Access 01-04-2014 | Original Paper

Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ)

Authors: Ina Zschocke, Ulrich Mrowietz, Annett Lotzin, Eleni Karakasili, Kristian Reich

Published in: Archives of Dermatological Research | Issue 3/2014

Login to get access

Abstract

Medication adherence rates strongly depend on favorable disease outcomes. It is known that medication adherence rates are lower for topical treatment than for systemic treatment. However, to date no validated instrument for the assessment of adherence factors in topical treatment is available. The aim of this study was to develop a new questionnaire to assess adherence risk factors in topical treatment. The development of the Topical Therapy Adherence Questionnaire (TTAQ) and Patient Preference Questionnaire (PPQ) was based on a systematic literature review, and qualitative patient focus interviews and expert focus groups’ input. The psychometric properties and comprehensibility of the TTAQ and PPQ were assessed in a feasibility study with 59 psoriasis patients. Our first preliminary results indicate that the TTAQ and PPQ are psychometrically sound and reliable measures for the assessment of factors influencing topical treatment adherence. The questionnaires are currently being further developed and various parameters (e.g., time point of assessment) are currently being tested in an exploratory pilot study with ca. 2,000 psoriasis patients receiving topical treatment in a European clinical trial. The use of the final versions of TTAQ and PPQ in clinical practice may facilitate the early identification of specific non-adherence factors in patients under topical treatment, which could enable designing and applying adherence-enhancing interventions according to the patient’s individual needs.
Appendix
Available only for authorised users
Literature
1.
Ashcroft DM, Li Wan PA, Williams HC, Griffiths CE (1998) Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 23:391–398PubMedCrossRef
2.
Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12PubMedCentralPubMedCrossRef
3.
Augustin M, Dieterle W, Zschocke I, Brill C, Trefzer D, Peschen M, Schopf E, Vanscheidt W (1997) Development and validation of a disease-specific questionnaire on the quality of life of patients with chronic venous insufficiency. Vasa 26:291–301PubMed
4.
Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA (2011) Adherence in the treatment of psoriasis: a systematic review. Dermatology 222:363–374PubMedCrossRef
5.
Augustin M, Lange S, Wenninger K, Seidenglanz K, Amon U, Zschocke I (2004) Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system. Eur J Dermatol 14:107–113PubMed
6.
Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schafer I, Reusch M, Mielke V, Rustenbach SJ (2009) The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 301:561–571
7.
Augustin M, Wenninger K, Amon U, Schroth MJ, Kuster W, Chren M, Kupfer J, Gieler U (2004) German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results. Dermatology 209:14–20PubMedCrossRef
8.
Barton GR, Hodgekins J, Mugford M, Jones PB, Croudace T, Fowler D (2009) Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ-5D. Br J Psychiatry 195:170–177PubMedCrossRef
9.
Bewley A, Page B (2011) Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 25:9–14PubMedCrossRef
10.
Brawley LR, Culos-Reed SN (2000) Studying adherence to therapeutic regimens: overview, theories, recommendations. Control Clin Trials 21:156S–163SPubMedCrossRef
11.
Bronsard V, Paul C, Prey S, Puzenat E, Gourraud PA, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Le MM, Richard-Lallemand MA, Ortonne JP (2010) What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 24(Suppl 2):17–22PubMedCrossRef
12.
Brown KK, Wingfield ER, Kimball AB (2006) Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 55:607–613PubMedCrossRef
13.
14.
Bryant LJ (2011) Medicines adherence–evidence for any intervention is disappointing. J Prim Health Care 3:240–243PubMed
15.
Butler RJ, Davis TK, Johnson WG, Gardner HH (2011) Effects of nonadherence with prescription drugs among older adults. Am J Manag Care 17:153–160PubMed
16.
Dimatteo MR, Giordani PJ, Lepper HS, Croghan TW (2002) Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 40:794–811PubMedCrossRef
17.
Dreno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, Leutenegger E, Perez M (2010) Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol 49:448–456PubMedCrossRef
18.
19.
Ersser SJ, Cowdell FC, Latter SM, Healy E (2010) Self-management experiences in adults with mild-moderate psoriasis: an exploratory study and implications for improved support. Br J Dermatol 163:1044–1049PubMedCrossRef
20.
Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R (2007) Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 57:81–83PubMedCrossRef
21.
Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, Menter A, van de Kerkhof PC (2008) Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 59:1009–1016PubMedCrossRef
22.
23.
Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)––a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210–216PubMedCrossRef
24.
Flowers B, Wand M, Piltz-Seymour J, Berke SJ, Day D, Teague J, Smoot TM, Landry TA, Bergamini MV, Mallick S (2006) Patients’ and physicians’ perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension. Clin Ther 28:1803–1811PubMedCrossRef
25.
Greenlaw SM, Yentzer BA, O’Neill JL, Balkrishnan R, Feldman SR (2010) Assessing adherence to dermatology treatments: a review of self-report and electronic measures. Skin Res Technol 16:253–258PubMedCrossRef
26.
Gupta G, Mallefet P, Kress DW, Sergeant A (2009) Adherence to topical dermatological therapy: lessons from oral drug treatment. Br J Dermatol 161:221–227PubMedCrossRef
27.
Hodari KT, Nanton JR, Carroll CL, Feldman SR, Balkrishnan R (2006) Adherence in dermatology: a review of the last 20 years. J Dermatol Treat 17:136–142CrossRef
28.
Hovstadius B, Petersson G (2011) Non-adherence to drug therapy and drug acquisition costs in a national population––a patient-based register study. BMC Health Serv Res 11:326 326PubMedCentralPubMedCrossRef
29.
Ingersoll KS, Cohen J (2008) The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 31:213–224PubMedCentralPubMedCrossRef
30.
Jank S, Bertsche T, Schellberg D, Herzog W, Haefeli WE (2009) The A14-scale: development and evaluation of a questionnaire for assessment of adherence and individual barriers. Pharm World Sci 31:426–431PubMedCrossRef
31.
Kjellgren KI, Ring L, Lindblad A, Maroti M, Serup J (2004) To follow dermatological treatment regimens––patients’ and providers’ views. Acta Derm Venereol 84:445–450PubMedCrossRef
32.
Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, Fleischer AB Jr, Balkrishnan R, Feldman SR (2007) Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 56:211–216PubMedCrossRef
33.
Lienert G (1969) Testaufbau und Testanalyse. Verlag Julius Beltz, Weinheim, Berlin, Basel
34.
Martin LR, Williams SL, Haskard KB, Dimatteo MR (2005) The challenge of patient adherence. Ther Clin Risk Manag 1:189–199PubMedCentralPubMed
35.
Matsui D (2009) Strategies to measure and improve patient adherence in clinical trials. Pharm Med 23:289–297CrossRef
36.
McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Griffiths CE, Van AD (2003) Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 149:323–331PubMedCrossRef
37.
Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, Bouter LM, de Vet HC (2006) Protocol of the COSMIN study: COnsensus-based standards for the selection of health measurement INstruments. BMC Med Res Methodol 6:2PubMedCentralPubMedCrossRef
38.
39.
Picardi A, Pasquini P (2007) Toward a biopsychosocial approach to skin diseases. Adv Psychosom Med 28:109–126PubMedCrossRef
40.
Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33:337–343PubMedCrossRef
41.
Renzi C, Picardi A, Abeni D, Agostini E, Baliva G, Pasquini P, Puddu P, Braga M (2002) Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 138:337–342PubMedCrossRef
42.
Ribera M, Dauden E, Puig L, Briones VG, Herranz JM, Bordas X, Vanaclocha F (2011) Design and validation of a questionnaire to measure treatment satisfaction in patients with moderate-to-severe psoriasis: the NEODERMA study. Actas Dermo-Sifiliográficas 102:28–38PubMed
43.
44.
Schmidt J, Lamprecht F, Wittmann WW (1989) Satisfaction with inpatient management. Development of a questionnaire and initial validity studies. Psychother Psychosom Med Psychol 39:248–255PubMed
45.
Storm A, Andersen SE, Benfeldt E, Serup J (2008) One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol 59:27–33PubMedCrossRef
46.
Zschocke I, Seidenglanz K, Lange S, Schiffler A, Amon U (2000) Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin diseases. Dermatol Psychosom 1:12–17CrossRef
Metadata
Title
Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ)
Authors
Ina Zschocke
Ulrich Mrowietz
Annett Lotzin
Eleni Karakasili
Kristian Reich
Publication date
01-04-2014
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 3/2014
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-014-1446-x

Other articles of this Issue 3/2014

Archives of Dermatological Research 3/2014 Go to the issue

Letter to the Editor

Validation of Dermaphot® for the assessment of steroid-induced skin atrophy

Review Article

Phytotherapy in the management of psoriasis: a review of the efficacy and safety of oral interventions and the pharmacological actions of the main plants

Original Paper

Willingness to pay and quality of life in patients with atopic dermatitis

Original Paper

Analysis of manganese superoxide dismutase (MnSOD Ala-9Val) and glutathione peroxidase (GPx1 Pro 198 Leu) gene polymorphisms in psoriasis

Original Paper

Clinical practice guidelines for treatment of acne vulgaris: a critical appraisal using the AGREE II instrument

Original Paper

Common variants of ZNF750, RPTOR and TRAF3IP2 genes and psoriasis risk